Actinium Pharmaceuticals Unveils ATNM-400 Updates at 2026 SNMMI Conference: A Step Forward in Targeted Cancer Therapies
Actinium Pharmaceuticals, a leader in the field of targeted radiotherapies, is preparing to present its latest updates on the ATNM-400 program during the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting scheduled for May 31 to June 2, 2026, in Los Angeles, California. This significant event is expected to highlight crucial new data regarding the first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400.
The schedule for this event includes multiple presentations that will underscore the differentiated profile of ATNM-400, particularly focusing on its application in prostate cancer and non-small cell lung cancer (NSCLC). The groundbreaking nature of this therapy is further emphasized by supporting data illustrating the effectiveness of radioconjugate optimization, which is vital in improving drug delivery and patient outcomes in various cancer treatments.
Sumit Mukherjee, Ph.D., from Actinium Pharmaceuticals, will lead one of the critical sessions titled, "ATNM-400: A First-in-Class Non-PSMA Actinium-225 Antibody Radioconjugate Demonstrates Superior Efficacy to PSMA-617 Radioligands and ARPIs With Favorable Safety Profile in Prostate Cancer Models." Scheduled for Tuesday, June 2, 2026, from 11:30 AM to 12:15 PM PT, this presentation promises to provide valuable insights into the therapeutic potential of ATNM-400 compared to existing treatments.
Additionally, a presentation titled "ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models," led by Shiva Kazerounian, Ph.D., will also take place on the same day. This presentation emphasizes the mutation-agnostic capabilities of ATNM-400, signifying its broad applicability across different tumor types without being limited by specific genetic mutations.
Second to these is another presentation focused on the optimization of the chelator-to-antibody ratio aimed at enhancing tumor targeting and pharmacokinetics of 225Ac-labeled antibodies. Kazerounian will present findings related to this optimization on Sunday, May 31, 2026, at the POPs and Science Pavilion Mixer. The significance of this presentation is critical, as it discusses methods to potentially increase the effectiveness of radiotherapeutic agents, illustrating how technological improvements can lead to better clinical outcomes.
Following the conference, the posters presented will be available on Actinium's website for public viewing, providing an excellent opportunity for further outreach and shared knowledge advancements in the oncology community.
In conjunction with the conference updates, Actinium Pharmaceuticals has also reported on its compliance status regarding NYSE American listing standards. The company received a notice indicating it is not in compliance with certain listing requirements due to insufficient stockholders' equity, which currently stands at approximately $2.3 million against the required threshold of $4.0 million. Actinium is in the process of drafting a compliance plan due by June 26, 2026, detailing the steps it will take to rectify this situation before the deadline of November 27, 2027.
Despite these regulatory challenges, the company remains committed to advancing its innovative treatments, driven by a mission to enhance cancer patient care through groundbreaking radiopharmaceuticals. Actinium’s unique approach combines insights into tumor biology with advanced radiochemistry to develop therapies aimed at improving both efficacy and safety in comparison to traditional cancer treatments.
This upcoming SNMMI 2026 conference is a pivotal moment for Actinium Pharmaceuticals, as it continues to push the boundaries of research and development in targeted cancer therapies while addressing essential compliance standards to ensure uninterrupted listings and investments in its promising initiatives. The outcomes from this conference are anticipated to provide critical data that may propel ATNM-400 and other pipeline candidates forward, making a significant impact in the realm of oncology.
The schedule for this event includes multiple presentations that will underscore the differentiated profile of ATNM-400, particularly focusing on its application in prostate cancer and non-small cell lung cancer (NSCLC). The groundbreaking nature of this therapy is further emphasized by supporting data illustrating the effectiveness of radioconjugate optimization, which is vital in improving drug delivery and patient outcomes in various cancer treatments.
Sumit Mukherjee, Ph.D., from Actinium Pharmaceuticals, will lead one of the critical sessions titled, "ATNM-400: A First-in-Class Non-PSMA Actinium-225 Antibody Radioconjugate Demonstrates Superior Efficacy to PSMA-617 Radioligands and ARPIs With Favorable Safety Profile in Prostate Cancer Models." Scheduled for Tuesday, June 2, 2026, from 11:30 AM to 12:15 PM PT, this presentation promises to provide valuable insights into the therapeutic potential of ATNM-400 compared to existing treatments.
Additionally, a presentation titled "ATNM-400: A First-in-Class Actinium-225 Antibody Radioconjugate Demonstrating Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer Models," led by Shiva Kazerounian, Ph.D., will also take place on the same day. This presentation emphasizes the mutation-agnostic capabilities of ATNM-400, signifying its broad applicability across different tumor types without being limited by specific genetic mutations.
Second to these is another presentation focused on the optimization of the chelator-to-antibody ratio aimed at enhancing tumor targeting and pharmacokinetics of 225Ac-labeled antibodies. Kazerounian will present findings related to this optimization on Sunday, May 31, 2026, at the POPs and Science Pavilion Mixer. The significance of this presentation is critical, as it discusses methods to potentially increase the effectiveness of radiotherapeutic agents, illustrating how technological improvements can lead to better clinical outcomes.
Following the conference, the posters presented will be available on Actinium's website for public viewing, providing an excellent opportunity for further outreach and shared knowledge advancements in the oncology community.
In conjunction with the conference updates, Actinium Pharmaceuticals has also reported on its compliance status regarding NYSE American listing standards. The company received a notice indicating it is not in compliance with certain listing requirements due to insufficient stockholders' equity, which currently stands at approximately $2.3 million against the required threshold of $4.0 million. Actinium is in the process of drafting a compliance plan due by June 26, 2026, detailing the steps it will take to rectify this situation before the deadline of November 27, 2027.
Despite these regulatory challenges, the company remains committed to advancing its innovative treatments, driven by a mission to enhance cancer patient care through groundbreaking radiopharmaceuticals. Actinium’s unique approach combines insights into tumor biology with advanced radiochemistry to develop therapies aimed at improving both efficacy and safety in comparison to traditional cancer treatments.
This upcoming SNMMI 2026 conference is a pivotal moment for Actinium Pharmaceuticals, as it continues to push the boundaries of research and development in targeted cancer therapies while addressing essential compliance standards to ensure uninterrupted listings and investments in its promising initiatives. The outcomes from this conference are anticipated to provide critical data that may propel ATNM-400 and other pipeline candidates forward, making a significant impact in the realm of oncology.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.